One South Carolina startup relies on the Southeastern U.S. history of engineering innovation, new infrastructure and quality of life to drive drug delivery innovation through nanoparticles.
Once home to a thriving textile industry replete with chemical and mechanical engineers working to improve the soil and machinery converting raw cotton into commercial goods, upstate South Carolina may be on the precipice of its next industrial revolution: medtech.
Born from technology developed at the Albert Einstein College of Medicine, Greenville-based Zylö Therapeutics is utilizing the regional chemical/mechanical engineering expertise and support network to improve drug and nitric oxide delivery through a proprietary sustained delivery system called Nanopods. Formally founded in late 2017, the company secured exclusive, worldwide rights to the technology and is currently working to solve the chemical and manufacturing issues that will enable scale-up and commercialization.
Here’s how Zylö Therapeutics describes the technology: “The delivery system uses patented hydrogel-derived nanoparticles, called Nanopods, to deliver—in a sustained and controlled manner—notoriously hard-to-deliver therapeutic agents through topical administration. With our system, Zylö has harnessed the powerhouse therapeutic, nitric oxide, as well as other therapeutics that have bioavailability challenges.”
To read more please click HERE.